Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

Tests inhaled TQC3721 in people with moderate-to-severe COPD

Tests an inhaled suspension against placebo in adults with moderate-to-severe COPD.

Plain-language title generated from the registry record
Registry title: Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Key facts

Where
Baoji, Baotou, Binzhou, Bozhou, Cangzhou, Changchun, Changsha, Changzhi, Chengdu, Chifeng, Chizhou, Chongqing, Dalian, Daqing, Foshan, Fuzhou, Guiyang, Haikou, Harbin, Hefei, Heze, Hohhot, Huizhou, Jiaozuo, Jiaxing, Jinhua, Jining, Jiujiang, Langfang, Lanzhou, Mianyang, Nanchang, Nanchong, Nanjing, Ningbo, Puyang, Qinhuangdao, Qiqihar, Shanghai, Shangqiu, Shaoxing, Shenyang, Shenzhen, Shihezi, Shijiazhuang, Suining, Taizhou, Tianjin, Weifang, Wenzhou, Wuxi, Xi'an, Xianyang, Xining, Xuzhou, Yangquan, Yangzhou, Yantai, Yichang, Yixing, Yongzhou, and Zhangzhou, ChinaSee the 76 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 80 years old?

Source: NCT07147946, who can take part

Where in China

  • Baoji Central HospitalBaoji, ChinaNo longer taking part
  • Baotou Central HospitalBaotou, ChinaNo longer taking part
  • Binzhou People's HospitalBinzhou, ChinaNo longer taking part
  • Bozhou People's HospitalBozhou, ChinaNo longer taking part
  • Cangzhou Hospital of Integrated TCM-WM·HebeiCangzhou, ChinaNo longer taking part
  • The First Hospital of Jilin UniversityChangchun, ChinaNo longer taking part
  • Hunan Provincial People's HospitalChangsha, ChinaNo longer taking part
  • Xiangya Hospital of Central South UniversityChangsha, ChinaNo longer taking part
  • Changzhi People's HospitalChangzhi, ChinaNo longer taking part
  • Chengdu Second People's HospitalChengdu, ChinaNo longer taking part
  • The First Affiliated Hospital of Chengdu Medical CollegeChengdu, ChinaNo longer taking part
  • West China Hospital of Sichuan UniversityChengdu, ChinaNo longer taking part
  • Chifeng Municipal HospitalChifeng, ChinaNo longer taking part
  • Chizhou People's HospitalChizhou, ChinaNo longer taking part
  • Chongqing University Three Gorges HospitalChongqing, ChinaNo longer taking part
  • Fuling Hospital Affiliated to Chongqing UniversityChongqing, ChinaNo longer taking part
  • Peolpe's Hospital Of Chongqing Banan DistrictChongqing, ChinaNo longer taking part
  • The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaNo longer taking part
  • Central Hospital of Dalian University of TechnologyDalian, ChinaNo longer taking part
  • Daqing Longnan HospitalDaqing, ChinaNo longer taking part
  • The Eighth Affiliated Hospital of Southern Medical University（The First people's Hospital of Shunde ）Foshan, ChinaNo longer taking part
  • Fujian Medical University Union HospitalFuzhou, ChinaNo longer taking part
  • Guizhou Provincial People's HospitalGuiyang, ChinaNo longer taking part
  • The First Affiliated Hospital of Hainan Medical UniversityHaikou, ChinaNo longer taking part
  • The First Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNo longer taking part
  • Chaohu Hospital of Anhui Medical UniversityHefei, ChinaNo longer taking part
  • Heze Municipal HospitalHeze, ChinaNo longer taking part
  • Inner Mongolia Medical University Affiliated HospitalHohhot, ChinaNo longer taking part
  • Huizhou Central People's HospitalHuizhou, ChinaNo longer taking part
  • Jiaozuo Second People's HospitalJiaozuo, ChinaNo longer taking part
  • The Second Hospital of JiaxingJiaxing, ChinaNo longer taking part
  • Dongyang People's HospitalJinhua, ChinaNo longer taking part
  • Jinhua Municipal Central HospitalJinhua, ChinaNo longer taking part
  • Affiliated Hospital of Jining Medical UniversityJining, ChinaNo longer taking part
  • Jiujiang First People's HospitalJiujiang, ChinaNo longer taking part
  • Hebei Petrochina Central HospitalLangfang, ChinaNo longer taking part
  • Gansu Provincial HospitalLanzhou, ChinaNo longer taking part
  • The First Hospital of Lanzhou UniversityLanzhou, ChinaNo longer taking part
  • Mianyang Central HospitalMianyang, ChinaNo longer taking part
  • Mianyang Hospital of Traditional Chinese MedicineMianyang, ChinaNo longer taking part
  • Jiangxi Provincial People's HospitalNanchang, ChinaNo longer taking part
  • The First Affiliated Hospital of NanChang UniversityNanchang, ChinaNo longer taking part
  • Affiliated Hospital of North Sichuan Medical CollegeNanchong, ChinaNo longer taking part
  • Nanjing Jiangning HospitalNanjing, ChinaNo longer taking part
  • The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaNo longer taking part
  • Puyang Oilfield General HospitalPuyang, ChinaNo longer taking part
  • The First Hospital of QinhuangdaoQinhuangdao, ChinaNo longer taking part
  • Qiqihar First HospitalQiqihar, ChinaNo longer taking part
  • Ruijin Hospital Shanghai Jiaotong University School of MedicineShanghai, ChinaNo longer taking part
  • Shanghai General HospitalShanghai, ChinaNo longer taking part
  • The First People's Hospital of ShangqiuShangqiu, ChinaNo longer taking part
  • Shaoxing People's HospitalShaoxing, ChinaNo longer taking part
  • Shengjing Hospital Of China Medical UniversityShenyang, ChinaNo longer taking part
  • Longgang District People's Hospital of ShenzhenShenzhen, ChinaNo longer taking part
  • Peking University Shenzhen HospitalShenzhen, ChinaNo longer taking part
  • The First Affiliated Hospital of Shihezi UniversityShihezi, ChinaNo longer taking part
  • Hebei medical university third hospitalShijiazhuang, ChinaNo longer taking part
  • Suining Central HospitalSuining, ChinaNo longer taking part
  • Taizhou Central HospitalTaizhou, ChinaNo longer taking part
  • Tianjin 4th Center HospitalTianjin, ChinaNo longer taking part
  • Tianjin Medical University General HospitalTianjin, ChinaNo longer taking part
  • Weifang NO.2 People's HospitalWeifang, ChinaNo longer taking part
  • The Second Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaNo longer taking part
  • Jiangyin Hospital of Traditional Chinese MedicineWuxi, ChinaNo longer taking part
  • The Fifth People's Hospital Of WuxiWuxi, ChinaNo longer taking part
  • Xi'an International Medical Center HospitalXi'an, ChinaNo longer taking part
  • Yan'an University Xianyang HospitalXianyang, ChinaNo longer taking part
  • Qinghai Provincial People's HospitalXining, ChinaNo longer taking part
  • Xuzhou Central HospitalXuzhou, ChinaNo longer taking part
  • Yangquan Coal Industry(Group) General HospitalYangquan, ChinaNo longer taking part
  • Subei People's Hospital of Jiangsu provinceYangzhou, ChinaNo longer taking part
  • Yantai Yuhuangding HospitalYantai, ChinaNo longer taking part
  • Yichang Central People's HospitalYichang, ChinaNo longer taking part
  • Yixing People's HospitalYixing, ChinaNo longer taking part
  • The Central Hospital of YongzhouYongzhou, ChinaNo longer taking part
  • Zhangzhou Municipal Hospital of Fujian ProvinceZhangzhou, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Trial code
NCT07147946
Record updated
10 September 2025
Original description
To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)Read full original descriptionShow less

Evaluation of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial on the Efficacy and Safety of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)

Inclusion: Sign an informed consent form before screening and fully understand the trial content, process, and potential adverse reactions; Comply with the experimental schedule and be able to use the nebulizer inhaler correctly; The age range is 40 to 80 years old (including the threshold), and both male and female participants are eligible; The subjects have no pregnancy plans and voluntarily take effective contraceptive measures for at least one month from screening to the last use of the study drug; Patients with a clear clinical history and related symptoms of COPD before screening; Capable of conducting acceptable and reproducible lung function tests; COPD clinical stability (no moderate to severe COPD acute exacerbation) within the 4 weeks prior to screening visit (V1 visit) and between V1 visit and V2 visit; Smoking history ≥ 10 pack years.

Exclusion: COPD acute exacerbations requiring systemic hormone therapy within 3 months prior to screening visit (V1 visit) or prior to randomization visit (V2 visit); Treatment with antibiotics for upper and/or lower respiratory tract infections within 6 weeks prior to screening or randomization visit (V3 visit); A history of life-threatening COPD, including admission to the intensive care unit and/or the need for intubation; Simultaneously suffering from other respiratory diseases; Previous lung resection or lung reduction surgery; 11.Previously received TQC3721 treatment. 12.Patients who received immunosuppressant therapy within 4 weeks prior to the screening period 13.In the investigator's assessment, patients are unable to discontinue the prohibited drugs specified in the protocol during the screening and treatment phases of the study; 14.Patients with a history of uncontrolled current diseases that the investigator judges to be clinically significant; 15.A history or current evidence of clinically significant cardiovascular or cerebrovascular diseases; 16.A history of malignant tumors (cured or uncured) in any organ or system within the past 5 years; 17.Intolerance or allergy to salbutamol or other inhaled bronchodilator therapies for COPD; 18.Patients requiring long-term oxygen therapy; 19.Female subjects who are currently pregnant, breastfeeding, or planning to become pregnant during the study period after enrollment; 20.Having participated in any clinical trial of drugs or medical devices within 4 weeks or 5 half-lives (whichever is longer) prior to the screening visit; 21.Other conditions deemed unsuitable for participation in the study by the investigator; Within the first 6 months of screening, there has been at least 1 hospitalization history due to acute exacerbation of COPD or pneumonia; Chest computed tomography (CT) revealed clinically significant abnormalities and concluded that the abnormalities were not caused by COPD.

ClinicalTrials.gov NCT07147946